Healthcare [ 5/13 ] | Drug Manufacturers - General [ 145/159 ]
NYSE | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 2, 24 | 2.79 Decreased by -22.5% | 2.77 Increased by +0.72% |
| Oct 27, 23 | 2.95 Decreased by -19.4% | 2.86 Increased by +3.15% |
| Jul 27, 23 | 2.91 Decreased by -13.65% | 2.81 Increased by +3.56% |
| Apr 27, 23 | 2.46 Decreased by -24.07% | 2.46 |
| Feb 9, 23 | 3.6 Increased by +8.76% | 3.56 Increased by +1.12% |
| Oct 28, 22 | 3.66 Increased by +9.91% | 3.57 Increased by +2.52% |
| Jul 29, 22 | 3.37 Increased by +9.06% | 3.31 Increased by +1.81% |
| Apr 29, 22 | 3.24 Increased by +9.83% | 3.14 Increased by +3.18% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 14.3 B Decreased by -5.42% | 822 M Decreased by -66.76% | Increased by +5.75% Decreased by -64.86% |
| Sep 30, 23 | 13.93 B Decreased by -5.97% | 1.78 B Decreased by -54.98% | Increased by +12.77% Decreased by -52.11% |
| Jun 30, 23 | 13.87 B Decreased by -4.92% | 2.02 B Increased by +119.05% | Increased by +14.6% Increased by +130.39% |
| Mar 31, 23 | 12.22 B Decreased by -9.7% | 239 M Decreased by -94.68% | Increased by +1.96% Decreased by -94.11% |
| Dec 31, 22 | 15.12 B Increased by +1.58% | 2.47 B Decreased by -38.85% | Increased by +16.35% Decreased by -39.8% |
| Sep 30, 22 | 14.81 B Increased by +3.28% | 3.95 B Increased by +24.22% | Increased by +26.66% Increased by +20.28% |
| Jun 30, 22 | 14.58 B Increased by +4.47% | 924 M Increased by +20.63% | Increased by +6.34% Increased by +15.47% |
| Mar 31, 22 | 13.54 B Increased by +4.06% | 4.49 B Increased by +26.3% | Increased by +33.17% Increased by +21.38% |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.